Article ISI
JOURNAL OF CLINICAL ONCOLOGY  (2021)

Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.

Garrido, Marcelo; Breder, Valeriy Vladimirovich; Rahman, Ahmadur

Más información

Título según WOS: Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.
Título de la Revista: JOURNAL OF CLINICAL ONCOLOGY
Volumen: 39
Número: 3
Editorial: LIPPINCOTT WILLIAMS & WILKINS
Fecha de publicación: 2021
DOI:

10.1200/JCO.2021.39.3_suppl.268
Notas: ISI